Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -9077.06% is 53% above its 1-year average of -19428.51%, near the high end of its 1-year range (-40431.63%–-3227.87%).
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2022 (2022-09-30): -3227.87%.
EBITDA MARGIN
-9077.06%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$262.65M
EBITDA Margin
-9077.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.06M
EBITDA Margin
-7643.91%
TTM Avg
-11162.31%
3Y Avg
-5581.16%
5Y Avg
-3720.77%
Market Cap
$261.05M
EBITDA Margin
-1857.26%
TTM Avg
-1020.57%
3Y Avg
-1032.24%
5Y Avg
-903.20%
Market Cap
$262.11M
EBITDA Margin
-5226.40%
TTM Avg
-5226.40%
3Y Avg
-5226.40%
5Y Avg
-21156.92%
Market Cap
$266.79M
EBITDA Margin
-50.56%
TTM Avg
-27.90%
3Y Avg
-8.82%
5Y Avg
-5.54%
Market Cap
$267.51M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$257.42M
EBITDA Margin
-4.72%
TTM Avg
-1.10%
3Y Avg
6.56%
5Y Avg
4.38%
Market Cap
$256.22M
EBITDA Margin
-1.78%
TTM Avg
-948.17%
3Y Avg
-2570.36%
5Y Avg
-2570.36%
Market Cap
$272.90M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $262.65M | -9077.06% | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.06M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
| AC Immune S.A. (ACIU)vs › | $261.05M | -1857.26% | -1020.57% | -1032.24% | -903.20% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -5226.40% | -5226.40% | -5226.40% | -21156.92% |
| OraSure Technologies, Inc. (OSUR)vs › | $266.79M | -50.56% | -27.90% | -8.82% | -5.54% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.51M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.42M | -4.72% | -1.10% | 6.56% | 4.38% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -1.78% | -948.17% | -2570.36% | -2570.36% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $272.90M | -768.62% | -551.06% | -374.75% | -290.29% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $248.50M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-9077.1%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-09-30 | -3227.87% |
| 2022-06-30 | -40431.63% |
| 2022-03-31 | -14626.02% |
